MEDIUM confidence: 100% data completeness, but the composite (54) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-12.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$28.4M over 180 days (0 open-market buys, 4 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Buy-rated share 100% → 100% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $0.99 | $0.97 | -2.1% |
| Jul 2026 | $0.89 | $0.90 | +1.4% |
| Apr 2026 | $1.00 | $0.97 | -3.0% |
| Feb 2026 | $1.14 | $1.14 | +0.0% |
| Oct 2025 | $0.83 | $0.87 | +4.8% |
| Jul 2025 | $0.84 | $0.88 | +4.8% |
| Apr 2025 | $0.90 | $0.96 | +6.7% |
| Feb 2025 | $1.06 | $1.06 | +0.0% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.1B— | $4.1B-0.8% | $4.1B-0.2% | $4.2B+2.1% | $4.3B+2.9% |
| EPS (dil.) | $4.72— | $3.53-25.2% | $3.53+0.0% | $3.53+0.0% | $3.80+7.6% |
| Free Cash Flow | $617M— | $456M-26.1% | $507M+11.2% | $556M+9.6% | $554M-0.3% |
| Gross Margin | 31.9% | 28.1%-3.8pp | 26.6%-1.5pp | 26.1%-0.6pp | 26.5%+0.4pp |
| Operating Margin | 28.7% | 22.6%-6.2pp | 23.0%+0.5pp | 22.2%-0.9pp | 22.6%+0.4pp |
| Net Margin | 19.4% | 13.8%-5.6pp | 13.1%-0.7pp | 12.4%-0.7pp | 12.6%+0.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 3.7%/yr (revenue basis).
Base free cash flow $539M (avg FY2023–FY2025; latest year $554M) · equity value $10.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 54 indicates a neutral outlook for SCI, driven by its strong profitability, with a high ROE of 41.2%, and relatively low risk, as evidenced by a beta of 0.8. However, the stock's value and growth scores are more subdued, with a P/E of 16.2 and revenue growth of 2.9%, respectively. The momentum score is also weighed down by a 12-month return of -4.3% and a recent 3-month decline of -10.8%. The long-term and short-term scores are closely aligned, suggesting a consistent view of the stock's prospects.